Component
Human dextromethorphan plasma AUC
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
In the six-person cocktail study, dextromethorphan AUC ratios after one 200-mg modafinil dose and seven daily doses were 0.97 and 0.78 (Table 4). The reported CYP2D6 interval interpretation is internally inconsistent; do not infer enzyme induction from this ratio alone.
Experimental context and source evidence
- evidence_access
- Primary abstract and PMC methods, Tables 3/4, results and discussion inspected; numerical inconsistency preserved in evidence-notes.json.
- experimental_contrast
- {"intervention": "Modafinil single dose and seven daily doses", "comparator": "Baseline without modafinil", "endpoint": "In the six-person cocktail study, dextromethorphan AUC ratios after one 200-mg modafinil dose and seven daily doses were 0.97 and 0.78 (Table 4). The reported CYP2D6 interval interpretation is internally inconsistent; do not infer enzyme induction from this ratio alone.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
- experimental_model
- Human repeated-measures pharmacokinetic study, six participants; one 200-mg dose versus seven 200-mg daily doses, each relative to baseline.
- interpretation_status
- Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
- limitations
- Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
- plain_language
- In the six-person cocktail study, dextromethorphan AUC ratios after one 200-mg modafinil dose and seven daily doses were 0.97 and 0.78 (Table 4). The reported CYP2D6 interval interpretation is internally inconsistent; do not infer enzyme induction from this ratio alone.
- primary_references
- Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol. | 2018 | DOI 10.1111/bcp.13478 | PMID 29178272 | https://pmc.ncbi.nlm.nih.gov/articles/PMC5809348/
- source_locator
- Reviewed reference lines 116-126; exact primary location described in quoted passage where extracted.
Modafinil: detailed mechanisms of action (reviewed 3 October 2026) · lines 116–126
Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Human repeated-measures pharmacokinetic study, six participants; one 200-mg dose versus seven 200-mg daily doses, each relative to baseline. · Recorded from source · Recorded from source
The six-participant human cocktail study compared baseline with one 200-mg dose and seven daily doses. **Table 4** reports the following AUC ratios: | Probe | Single dose | Seven doses | |---|---:|---:| | Caffeine | 0.95 | 0.88 | | Dextromethorphan | 0.97 | 0.78 | | Losartan | 0.96 | 0.97 | | Midazolam | 0.97 | 0.65 | | Omeprazole | 1.36 | 1.85 | These support time-dependent CYP3A induction and CYP2C19 inhibition. The abstract's estimates differ slightly; the draft's approximately 34%/90% changes follow the abstract. **Source discrepancy:** the discussion calls the dextromethorphan interval 0.69–0.88 contained within 0.85–1.20. That statement is mathematically false. Retain the measurement and query the analysis; do not promote it directly to proven CYP2D6 induction or a definite null. [Trial, Table 4 and discussion](https://pmc.ncbi.nlm.nih.gov/articles/PMC5809348/)
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.